Esperion Therapeutics (ESPR) Equity Average: 2018-2025
Historic Equity Average for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to -$442.4 million.
- Esperion Therapeutics' Equity Average fell 23.86% to -$442.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$442.4 million, marking a year-over-year decrease of 23.86%. This contributed to the annual value of -$421.9 million for FY2024, which is 8.34% down from last year.
- Per Esperion Therapeutics' latest filing, its Equity Average stood at -$442.4 million for Q3 2025, which was down 2.93% from -$429.9 million recorded in Q2 2025.
- Esperion Therapeutics' Equity Average's 5-year high stood at -$182.8 million during Q1 2021, with a 5-year trough of -$442.4 million in Q3 2025.
- Moreover, its 3-year median value for Equity Average was -$379.5 million (2024), whereas its average is -$382.9 million.
- Per our database at Business Quant, Esperion Therapeutics' Equity Average plummeted by 1,727.85% in 2021 and then grew by 12.26% in 2024.
- Esperion Therapeutics' Equity Average (Quarterly) stood at -$279.8 million in 2021, then declined by 10.40% to -$308.9 million in 2022, then crashed by 39.99% to -$432.5 million in 2023, then rose by 12.26% to -$379.5 million in 2024, then decreased by 23.86% to -$442.4 million in 2025.
- Its Equity Average was -$442.4 million in Q3 2025, compared to -$429.9 million in Q2 2025 and -$407.5 million in Q1 2025.